Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;33(4):884-892.
doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28.

Inotuzumab Ozogamicin in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Affiliations
Free PMC article

Inotuzumab Ozogamicin in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Deepa Bhojwani et al. Leukemia. .
Free PMC article

Erratum in

Abstract

Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use program. In this heavily pretreated cohort, complete remission was achieved in 67% of patients with overt marrow disease. The majority (71%) of responders were negative for minimal residual disease. Responses were observed irrespective of cytogenetic subtype or number or type of prior treatment regimens. InO was well-tolerated; grade 3 hepatic transaminitis or hyperbilirubinemia were noted in 6 (12%) and grade 3/4 infections in 11 (22%) patients. No patient developed sinusoidal obstruction syndrome (SOS) during InO therapy; however, 11 of 21 (52%) patients who underwent hematopoietic stem cell transplantation (HSCT) following InO developed SOS. Downregulation of surface CD22 was detected as a possible escape mechanism in three patients who developed a subsequent relapse after InO. We conclude that InO is a well-tolerated, effective therapy for children with relapsed ALL and prospective studies are warranted. Identification of risk factors for developing post-HSCT SOS and strategies to mitigate this risk are ongoing.

Conflict of interest statement

MMO’B, EAR, MLL, and SRR have received research funding from Pfizer Inc. for different studies through grant mechanisms. Pfizer did not provide any financial support for this retrospective review of their compassionate use program. The remaining authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
EFS (a) and OS (b). The 12-month EFS and OS rates for the entire cohort of 51 patients were 23.4 ± 7.5% and 36.3 ± 9.3%, respectively
Fig. 2
Fig. 2
CD22 expression at relapse post-InO. CD22 expression in two patients evaluated pre- and post- InO and in one patient post-InO. CD22 is uniformly expressed on >99% B-lymphoblastic leukemia cells prior to InO (a, d); however, CD22 expression is diminished or absent (b, c, e) or absent in a subset of lymphoblasts (f) after InO

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

References

    1. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14:e205–17. doi: 10.1016/S1470-2045(12)70580-6. - DOI - PubMed
    1. Sun Weili, Malvar Jemily, Sposto Richard, Verma Anupam, Wilkes Jennifer J., Dennis Robyn, Heym Kenneth, Laetsch Theodore W., Widener Melissa, Rheingold Susan R, Oesterheld Javier, Hijiya Nobuko, Sulis Maria Luisa, Huynh Van, Place Andrew E., Bittencourt Henrique, Hutchinson Raymond, Messinger Yoav, Chang Bill, Matloub Yousif, Ziegler David S., Gardner Rebecca, Cooper Todd, Ceppi Francesco, Hermiston Michelle, Dalla-Pozza Luciano, Schultz Kirk R., Gaynon Paul, Wayne Alan S., Whitlock James A. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32(11):2316–2325. doi: 10.1038/s41375-018-0094-0. - DOI - PMC - PubMed
    1. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28:648–54. doi: 10.1200/JCO.2009.22.2950. - DOI - PMC - PubMed
    1. Dahl Jenny, Marx Kayleigh, Jabbour Elias. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Review of Hematology. 2016;9(4):329–334. doi: 10.1586/17474086.2016.1143771. - DOI - PubMed
    1. Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005;88:1–50. doi: 10.1016/S0065-2776(05)88001-0. - DOI - PubMed

MeSH terms

Substances

Feedback